Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
To compare in a randomized prospective study the effectiveness and toxicity of Thymoglobulin
vs. Campath-1H used for induction therapy vs. our conventional therapy in recipients of first
cadaver (CAD) kidneys.
Phase:
Phase 4
Details
Lead Sponsor:
University of Miami
Treatments:
Alemtuzumab Calcineurin Inhibitors Daclizumab Immunoglobulin G Thymoglobulin